NASDAQ · LUMO
Healthcare · Biotechnology
$4.34
Up+$0.00 (+0.00%)
Updated Sep 17, 2026, 10:48 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
LUMO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning LUMO.
LUMO research
Company profile and research snapshot.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 8, 2024 | HC Wainwright & Co. | Neutral | — |
| Oct 24, 2024 | HC Wainwright & Co. | Neutral | — |
| Oct 23, 2024 | Jones Trading | Hold | — |
| Sep 27, 2024 | HC Wainwright & Co. | Buy | — |
| Sep 24, 2024 | EF Hutton | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Nov 6, 2024
Monteverde & Associates PC is investigating the proposed merger between Lumos Pharma Inc. (NYSE: LUMO) and Double Point Ventures LLC, where Double Point Ventures will acquire Lumos Pharma's outstanding shares for $4.25 per share in cash, plus one non-transferable unsecured Contingent Value Right per share.
GlobeNewswire Inc. · Aug 15, 2024
Lumos Pharma, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, where it will host one-on-one meetings and present its corporate overview.
GlobeNewswire Inc. · May 20, 2024
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024.
GlobeNewswire Inc. · May 14, 2024
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LUMO.
No results
No recent SID articles mention LUMO.
